ID

32120

Descripción

Study ID: 106218 Clinical Study ID: TDC106218 Study Title: Study On Bioavailability And Pharmacokinetics Of Various Doses Of Testosterone Administered With And Without Dutasteride  Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier:  Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: testosterone Trade Name: Andropatch,Androderm Study Indication: Hypogonadism, Male

Palabras clave

  1. 19/10/18 19/10/18 -
  2. 16/11/18 16/11/18 -
  3. 19/1/19 19/1/19 -
  4. 4/3/19 4/3/19 -
Titular de derechos de autor

GSK group of companies

Subido en

19 de octubre de 2018

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY-NC 3.0

Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Bioavailability and Pharmacokinetics of Testosterone with/without Dutasteride - 106218

Serious Adverse Event Form

Administrative data
Descripción

Administrative data

Subject Identifier
Descripción

Subject Identifier

Tipo de datos

integer

Centre Number
Descripción

Centre Number

Tipo de datos

integer

Randomisation Number
Descripción

Randomisation Number

Tipo de datos

integer

Serious Adverse Event (SAE)
Descripción

Serious Adverse Event (SAE)

Did the subject experience a serious adverse event during the study?
Descripción

Did the subject experience a serious adverse event during the study?

Tipo de datos

boolean

If YES, record details below
Descripción

If YES, record details below

Tipo de datos

text

Section 1
Descripción

Section 1

Event
Descripción

Diagnosis Only (if known) Otherwise Sign/Symptom. e.g., Anaphylaxis

Tipo de datos

text

Start Date
Descripción

e.g., 25 JAN 03

Tipo de datos

date

Outcome
Descripción

e.g., 1

Tipo de datos

integer

End Date
Descripción

If FATAL, record date of death. e.g., 27 JAN 03

Tipo de datos

date

Maximum Intensity
Descripción

e.g., 1

Tipo de datos

integer

Action Taken with Investigational Product(s) as a Result of the SAE
Descripción

e.g., 4

Tipo de datos

integer

Withdrawal - Did the subject withdraw from study as a result of this SAE?
Descripción

Withdrawal - Did the subject withdraw from study as a result of this SAE?

Tipo de datos

boolean

Relationship to Investigational Product(s)) - Is there a reasonable possibility the SAE may have been caused by the investigational product?
Descripción

Relationship to Investigational Product(s) - Is there a reasonable possibility the SAE may have been caused by the investigational product?

Tipo de datos

boolean

Other
Descripción

Other

Complete Study Conclusion page and mark Adverse event as reason for withdrawal.
Descripción

Complete Study Conclusion page and mark Adverse event as reason for withdrawal.

Tipo de datos

text

If FATAL, was a post-mortem/autopsy performed?
Descripción

If FATAL, was a post-mortem/autopsy performed?

Tipo de datos

boolean

If YES, summarise findings in Section 11 Narrative Remarks of this SAE form.
Descripción

If YES, summarise findings in Section 11 Narrative Remarks of this SAE form.

Tipo de datos

text

Section 2
Descripción

Section 2

Seriousness (specify reason(s) for considering this a SAE, mark all that apply)
Descripción

Seriousness (specify reason(s) for considering this a SAE, mark all that apply)

Tipo de datos

text

Section 3
Descripción

Section 3

Demography Data
Descripción

Demography Data

Tipo de datos

text

Date of birth
Descripción

Date of birth

Tipo de datos

date

Sex
Descripción

Sex

Tipo de datos

integer

Weight
Descripción

Weight

Tipo de datos

float

Unidades de medida
  • kg
kg
Section 4
Descripción

Section 4

If investigational Product(s) was Stopped, Did the Reported Event(s) Recur After Further Investigational Product(s) were Administered?
Descripción

If investigational Product(s) was Stopped, Did the Reported Event(s) Recur After Further Investigational Product(s) were Administered?

Tipo de datos

text

Section 5
Descripción

Section 5

Possible causes of SAE Other Than Investigational Product(s), mark all that apply:
Descripción

Possible causes of SAE Other Than Investigational Product(s), mark all that apply:

Tipo de datos

text

Section 6
Descripción

Section 6

Relevant medical conditions
Descripción

Relevant medical conditions

Tipo de datos

text

Specify any relevant past or current medical disorders, allergies, surgeries, etc. that can help explain the SAE
Descripción

Specify any relevant past or current medical disorders, allergies, surgeries, etc. that can help explain the SAE

Tipo de datos

text

Date of Onset
Descripción

Date of Onset

Tipo de datos

date

Condition Present at Time of the SAE?
Descripción

Condition Present at Time of the SAE?

Tipo de datos

date

If NO, Date of Last Occurrence
Descripción

If NO, Date of Last Occurrence

Tipo de datos

date

Section 7
Descripción

Section 7

Other Relevant Risk Factors
Descripción

Provide any family or social history (e.g., smoking, alcohol, diet, drug abuse, occupational hazard) relevant to the SAE

Tipo de datos

text

Section 8
Descripción

Section 8

Relevant Concomitant Medications
Descripción

Include detail of any concomitant medication(s) which may have contributed to the event

Tipo de datos

text

Drug Name
Descripción

Trade name preferred. e.g., Zantac

Tipo de datos

text

Dose
Descripción

e.g., 150

Tipo de datos

integer

Unit
Descripción

e.g., mg

Tipo de datos

text

Frequency
Descripción

Frequency

Tipo de datos

text

Route
Descripción

Route

Tipo de datos

text

Taken Prior to Study?
Descripción

Taken Prior to Study?

Tipo de datos

boolean

Start Day
Descripción

e.g., 27 JAN 03

Tipo de datos

date

Stop Date
Descripción

e.g., 27 JAN 03

Tipo de datos

date

Ongoing Medication?
Descripción

Ongoing Medication?

Tipo de datos

boolean

Reason for Medication
Descripción

e.g., Gastric ulcer

Tipo de datos

text

Section 9
Descripción

Section 9

Details of Investigational Product(s)
Descripción

Enter details for Part 1 OR Part 2

Tipo de datos

text

Part 1 - Investigational Product
Descripción

Part 1 - Investigational Product

Tipo de datos

text

Treatment Period
Descripción

Treatment Period

Tipo de datos

integer

Treatment Group (A, B or C)
Descripción

Treatment Group (A, B or C)

Tipo de datos

text

Start Date of Dose
Descripción

Start Date of Dose

Tipo de datos

date

Part 2 - Investigation Product
Descripción

Part 2 - Investigation Product

Tipo de datos

text

Treatment Period
Descripción

Treatment Period

Tipo de datos

text

Start Date
Descripción

Start Date

Tipo de datos

date

Stop Date
Descripción

Stop Date

Tipo de datos

date

Section 10
Descripción

Section 10

Details of Relevant Assessment
Descripción

Provide details of any other tests/procedures which were carried out to diagnose or onfirm the SAE e.g., laboratory data with units and normal range

Tipo de datos

text

Section 11
Descripción

Section 11

Narrative Remarks
Descripción

Provide a brief narrative description of the SAE and details of treatment given

Tipo de datos

text

Investigator's confirmation
Descripción

Investigator's confirmation

Investigator's signature
Descripción

confirming that the data on the SAE pages are accurate and complete

Tipo de datos

text

Date
Descripción

Date

Tipo de datos

date

Investigator's name (print)
Descripción

Investigator's name (print)

Tipo de datos

text

Similar models

Serious Adverse Event Form

Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
Administrative data
Subject Identifier
Item
Subject Identifier
integer
Centre Number
Item
Centre Number
integer
Randomisation Number
Item
Randomisation Number
integer
Item Group
Serious Adverse Event (SAE)
Did the subject experience a serious adverse event during the study?
Item
Did the subject experience a serious adverse event during the study?
boolean
If YES, record details below
Item
If YES, record details below
text
Item Group
Section 1
Event
Item
Event
text
Start Date
Item
Start Date
date
Item
Outcome
integer
Code List
Outcome
CL Item
Recovered/Resolved (1)
CL Item
Recovering/Resolving (2)
CL Item
Not Recovered/Not Resolved (3)
CL Item
Recovered/Resolved with sequelae (4)
CL Item
Fatal (5)
End Date
Item
End Date
date
Item
Maximum Intensity
integer
Code List
Maximum Intensity
CL Item
[1] Mild (1)
CL Item
[2] Moderate (2)
CL Item
[3] Severe (3)
CL Item
[X] Not applicable (4)
Item
Action Taken with Investigational Product(s) as a Result of the SAE
integer
Code List
Action Taken with Investigational Product(s) as a Result of the SAE
CL Item
[1] Investigational product(s) withdrawn (1)
CL Item
[2] Dose reduced (2)
CL Item
[3] Dose increased (3)
CL Item
[4] Dose not changed (4)
CL Item
[5] Dose interrupted (5)
CL Item
[X] Not applicable (6)
Withdrawal - Did the subject withdraw from study as a result of this SAE?
Item
Withdrawal - Did the subject withdraw from study as a result of this SAE?
boolean
Relationship to Investigational Product(s) - Is there a reasonable possibility the SAE may have been caused by the investigational product?
Item
Relationship to Investigational Product(s)) - Is there a reasonable possibility the SAE may have been caused by the investigational product?
boolean
Item Group
Other
Complete Study Conclusion page and mark Adverse event as reason for withdrawal.
Item
Complete Study Conclusion page and mark Adverse event as reason for withdrawal.
text
If FATAL, was a post-mortem/autopsy performed?
Item
If FATAL, was a post-mortem/autopsy performed?
boolean
If YES, summarise findings in Section 11 Narrative Remarks of this SAE form.
Item
If YES, summarise findings in Section 11 Narrative Remarks of this SAE form.
text
Item Group
Section 2
Item
Seriousness (specify reason(s) for considering this a SAE, mark all that apply)
text
Code List
Seriousness (specify reason(s) for considering this a SAE, mark all that apply)
CL Item
[A] result in death (1)
CL Item
[B] Is life-threatening (2)
CL Item
[C] Requires hospitalisation or prolongation of existing hospitalisation (3)
CL Item
[D] Results in disability/incapacity (4)
CL Item
[E] Congenital anomaly/birth defect (5)
CL Item
[F] other, specify___________________________________ (6)
Item Group
Section 3
Demography Data
Item
Demography Data
text
Date of birth
Item
Date of birth
date
Item
Sex
integer
Code List
Sex
CL Item
Male (1)
CL Item
Female (2)
Weight
Item
Weight
float
Item Group
Section 4
Code List
If investigational Product(s) was Stopped, Did the Reported Event(s) Recur After Further Investigational Product(s) were Administered?
CL Item
Yes (1)
CL Item
No (2)
CL Item
Unknown at this time (3)
CL Item
Not applicable (4)
Item Group
Section 5
Item
Possible causes of SAE Other Than Investigational Product(s), mark all that apply:
text
Code List
Possible causes of SAE Other Than Investigational Product(s), mark all that apply:
CL Item
Disease under study (1)
CL Item
Medical condition(s) specify_____________________(record in Section 6) (2)
CL Item
Lack of efficacy (3)
CL Item
Withdrawal of investigational product(s) (4)
CL Item
Concomitant medication(s) specify_________________(record in section 8) (5)
CL Item
Activity related to study participation (e.g., procedures) (6)
CL Item
Other, specify_________________________________________________ (7)
Item Group
Section 6
Relevant medical conditions
Item
Relevant medical conditions
text
Specify any relevant past or current medical disorders, allergies, surgeries, etc. that can help explain the SAE
Item
Specify any relevant past or current medical disorders, allergies, surgeries, etc. that can help explain the SAE
text
Date of Onset
Item
Date of Onset
date
Condition Present at Time of the SAE?
Item
Condition Present at Time of the SAE?
date
If NO, Date of Last Occurrence
Item
If NO, Date of Last Occurrence
date
Item Group
Section 7
Other Relevant Risk Factors
Item
Other Relevant Risk Factors
text
Item Group
Section 8
Relevant Concomitant Medications
Item
Relevant Concomitant Medications
text
Drug Name
Item
Drug Name
text
Dose
Item
Dose
integer
Unit
Item
Unit
text
Frequency
Item
Frequency
text
Route
Item
Route
text
Taken Prior to Study?
Item
Taken Prior to Study?
boolean
Start Day
Item
Start Day
date
Stop Date
Item
Stop Date
date
Ongoing Medication?
Item
Ongoing Medication?
boolean
Reason for Medication
Item
Reason for Medication
text
Item Group
Section 9
Details of Investigational Product(s)
Item
Details of Investigational Product(s)
text
Part 1 - Investigational Product
Item
Part 1 - Investigational Product
text
Treatment Period
Item
Treatment Period
integer
Treatment Group (A, B or C)
Item
Treatment Group (A, B or C)
text
Start Date of Dose
Item
Start Date of Dose
date
Part 2 - Investigation Product
Item
Part 2 - Investigation Product
text
Treatment Period
Item
Treatment Period
text
Start Date
Item
Start Date
date
Stop Date
Item
Stop Date
date
Item Group
Section 10
Details of Relevant Assessment
Item
Details of Relevant Assessment
text
Item Group
Section 11
Narrative Remarks
Item
Narrative Remarks
text
Item Group
Investigator's confirmation
Investigator's signature
Item
Investigator's signature
text
Date
Item
Date
date
Investigator's name (print)
Item
Investigator's name (print)
text

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial